<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

20057,166 citationsJournal Articlebronze Open Access

Authors

Monika E. Hegi · University Hospital of Lausanne

Annie‐Claire Diserens

Thierry Gorlia

Marie‐France Hamou

Nicolas de Tribolet · University Hospital of Geneva

Michael Weller · University of Tübingen

Johan M. Kros · Rotterdam University of Applied Sciences

Johannes A. Hainfellner · Medical University of Vienna

Abstract

Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.

Topics & Keywords

Glioma Diagnosis and Treatment Epigenetics and DNA Methylation Histone Deacetylase Inhibitors Research

Publication Details

Published in: New England Journal of Medicine

Volume 352, Issue 10, pp. 997-1003

DOI: 10.1056/nejmoa043331

Field-Weighted Citation Impact: 84.44

Command Palette

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

Authors

Abstract

Topics & Keywords

Publication Details